Characteristics of de novo DLBCL patients in the NCCN and BCCA cohorts
| Cohort characteristics . | NCCN (n = 1650) . | BCCA (n = 1138) . |
|---|---|---|
| Male gender | 54% | 60% |
| Age (y), mean (SD) | 57 (16) | 63 (15) |
| Age >60 y, % | 46% | 60% |
| LDH ratio >1, % | 50% | 49% |
| Ann Arbor stage (III-IV), % | 59% | 55% |
| ECOG PS (≥2), % | 11% | 37% |
| Extranodal disease,* % | 36% | 25% |
| Cohort characteristics . | NCCN (n = 1650) . | BCCA (n = 1138) . |
|---|---|---|
| Male gender | 54% | 60% |
| Age (y), mean (SD) | 57 (16) | 63 (15) |
| Age >60 y, % | 46% | 60% |
| LDH ratio >1, % | 50% | 49% |
| Ann Arbor stage (III-IV), % | 59% | 55% |
| ECOG PS (≥2), % | 11% | 37% |
| Extranodal disease,* % | 36% | 25% |
Lymphomatous involvement in the bone marrow, CNS, liver/GI tract, or lung.